- Home
- RNA vs IVZ Comparison
RNA vs IVZ Comparison
Compare RNA & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNA | IVZ |
|---|---|---|
| Founded | 2012 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 13.1B |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RNA | IVZ |
|---|---|---|
| Price | $14.93 | $23.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 15 |
| Target Price | ★ $69.26 | $27.47 |
| AVG Volume (30 Days) | 2.9M | ★ 4.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.40% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,314,100,000.00 |
| Revenue This Year | $88.12 | N/A |
| Revenue Next Year | $18.11 | $5.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.98 |
| 52 Week Low | $13.06 | $11.60 |
| 52 Week High | $73.06 | $29.61 |
Technical Indicators
Market Signals| Indicator | RNA | IVZ |
|---|---|---|
| Relative Strength Index (RSI) | 4.22 | 31.70 |
| Support Level | $13.06 | $22.12 |
| Resistance Level | $72.52 | $24.67 |
| Average True Range (ATR) | 0.83 | 0.93 |
| MACD | -6.15 | -0.23 |
| Stochastic Oscillator | 3.11 | 10.12 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients. At the end of November 2025, the firm had $2.154 trillion in assets under management spread among its equity (62% of AUM), balanced (3%), fixed-income (20%), alternative investment (6%), and money market (9%) operations. Passive products account for close to half of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 31% of its AUM sourced from Europe, Africa, and the Middle East (16%) and Asia (15%).